Bristol Myers Squibb (CELG-RI) EBT (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly EBT of $4.1 billion for Q2 2026, up 130.46% year-over-year from $1.8 billion in Q2 2025, and up 26.11% quarter-over-quarter from $3.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) EBT (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported EBT for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT rose 130.46% year-over-year to $4.1 billion; the TTM figure through Jun 2026 stood at $11.9 billion (up 80.59% YoY), while the FY2025 annual figure was $9.3 billion, up 211.33% from the prior year.
- EBT improved to $4.1 billion in Q2 2026 per CELG-RI's latest filing, from $3.2 billion in the prior quarter.
- Across five years, EBT topped out at $4.1 billion in Q2 2026 and bottomed at -$11.5 billion in Q1 2024.
- Historically, EBT has averaged $1.4 billion across 5 years, with a median of $1.9 billion in 2022.
- Annual changes were most pronounced in 2024 — EBT plunged 515.74% — and 2025, when it surged 740.0%.
- Bristol Myers Squibb's EBT stood at $1.9 billion in 2022, then decreased by 9.95% to $1.7 billion in 2023, then slumped by 89.55% to $175.0 million in 2024, then soared by 740.0% to $1.5 billion in 2025, then soared by 177.96% to $4.1 billion in 2026.
- Business Quant data shows CELG-RI's EBT at $4.1 billion in Q2 2026, $3.2 billion in Q1 2026, and $1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 6.75 Bn |
| 2 | AbbVie | 470.06 Bn | 463.49 Bn | 12.70 Bn | 4.28 Bn |
| 3 | Merck | 377.53 Bn | 370.39 Bn | 12.21 Bn | -683.00 Mn |
| 4 | Novartis Ag | 302.81 Bn | 295.12 Bn | 11.24 Bn | 4.27 Bn |
| 5 | Astrazeneca | 258.33 Bn | 253.43 Bn | 12.86 Bn | 2.80 Bn |
| 6 | Amgen | 237.17 Bn | 223.18 Bn | 7.24 Bn | 2.77 Bn |
| 7 | Gilead Sciences | 183.44 Bn | 180.26 Bn | 6.22 Bn | -10.25 Bn |
| 8 | Pfizer | 160.60 Bn | 148.90 Bn | 10.94 Bn | -653.00 Mn |
| 9 | Gsk | 106.09 Bn | 101.92 Bn | 8.24 Bn | 474.95 Mn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 4.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.09 Bn |
| Mar 31, 2026 | 3.24 Bn |
| Dec 31, 2025 | 1.47 Bn |
| Sep 30, 2025 | 3.11 Bn |
| Jun 30, 2025 | 1.77 Bn |
| Mar 31, 2025 | 2.97 Bn |
| Dec 31, 2024 | 175.00 Mn |
| Sep 30, 2024 | 1.68 Bn |
| Jun 30, 2024 | 1.29 Bn |
| Mar 31, 2024 | -11.52 Bn |
| Dec 31, 2023 | 1.67 Bn |
| Sep 30, 2023 | 2.14 Bn |
| Jun 30, 2023 | 1.86 Bn |
| Mar 31, 2023 | 2.77 Bn |
| Dec 31, 2022 | 1.86 Bn |
| Sep 30, 2022 | 2.21 Bn |
| Jun 30, 2022 | 1.96 Bn |
| Mar 31, 2022 | 1.69 Bn |
| Dec 31, 2021 | 1.86 Bn |
| Sep 30, 2021 | 2.16 Bn |